Literature DB >> 10684961

Innate antibody catalysis.

G Gololobov1, M Sun, S Paul.   

Abstract

Catalysis by antibodies is often assumed to require immunization with artificial haptens, which are proposed to stimulate adaptive immune processes and enable the development of catalytic sites with the ability to bind the transition state. Contrary to this assumption, we describe here a serine protease-like catalytic triad in an antibody light chain raised by immunization with vasoactive intestinal peptide (VIP), the structure and function of which is inherited via a germline V(L) gene. The serine protease mechanism was evident from loss of the catalytic activity by site directed mutagenesis at a framework region residue Asp1 (present study) and at two complementarity determining region residues Ser27a and His 93 (Gao, Q-S., Sun, M., Rees, A., Paul, S., 1995. Site-directed mutagenesis of proteolytic antibody light chain. J. Mol. Biol. 253, 658-664). All three catalytic residues (Ser27a, His93, Asp1) are also present in the germline counterpart of the mature V(L) gene, but the mature and germline sequences differ by four amino acids remote from the catalytic site. Reversion mutations were introduced at these amino acids in the mature light chain (His27 d:Asp, Thr28e:Ser, Ile34:Asn, Gln96:Trp; Kabat numbering, germline encoded residues shown second), generating the germline configuration of the protein. The germline light chain expressed peptidase activity, determined by assaying the cleavage of VIP and a synthetic protease substrate, Pro-Phe-Arg-Methylcoumarinamide. Differences between the kinetic constants for the mature and germline light chains were marginal. Diisopropylfluorophosphate, a serine protease inhibitor, blocked the peptidase activity of the germline light chain, suggesting the presence of the catalytic triad in a functional state. Like the mature light chain, the germline protein preferentially cleaves peptide bonds on the C-terminal side of basic residues. We conclude that the catalytic activity of certain antibodies is an innate function, originating over the course of phylogenetic evolution of the V(L) genes, as opposed to somatic processes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10684961     DOI: 10.1016/s0161-5890(99)00141-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection.

Authors:  Eric L Brown; Yasuhiro Nishiyama; Jesse W Dunkle; Shreya Aggarwal; Stephanie Planque; Kenji Watanabe; Keri Csencsits-Smith; M Gabriela Bowden; Sheldon L Kaplan; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

Review 2.  Antibodies as defensive enzymes.

Authors:  Sudhir Paul; Yasuhiro Nishiyama; Stephanie Planque; Sangeeta Karle; Hiroaki Taguchi; Carl Hanson; Marc E Weksler
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

3.  A human germ line antibody light chain with hydrolytic properties associated with multimerization status.

Authors:  Vikram Sharma; William Heriot; Kirk Trisler; Vaughn Smider
Journal:  J Biol Chem       Date:  2009-10-02       Impact factor: 5.157

4.  Constant domain-regulated antibody catalysis.

Authors:  Gopal Sapparapu; Stephanie Planque; Yukie Mitsuda; Gary McLean; Yasuhiro Nishiyama; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-09-04       Impact factor: 5.157

Review 5.  Beneficial catalytic immunity to abeta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

6.  Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies.

Authors:  Yukie Mitsuda; Stephanie Planque; Mariko Hara; Robert Kyle; Hiroaki Taguchi; Yasuhiro Nishiyama; Sudhir Paul
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

Review 7.  Catalytic antibodies to HIV: physiological role and potential clinical utility.

Authors:  Stephanie Planque; Yasuhiro Nishiyama; Hiroaki Taguchi; Maria Salas; Carl Hanson; Sudhir Paul
Journal:  Autoimmun Rev       Date:  2008-04-29       Impact factor: 9.754

8.  Physiological IgM class catalytic antibodies selective for transthyretin amyloid.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Mariko Hara; Sari Sonoda; Sarah K Murphy; Kenji Watanabe; Yukie Mitsuda; Eric L Brown; Richard J Massey; Stanley R Primmer; Brian O'Nuallain; Sudhir Paul
Journal:  J Biol Chem       Date:  2014-03-19       Impact factor: 5.157

9.  CD4 binding determinant mimicry for HIV vaccine design.

Authors:  Yasuhiro Nishiyama; Stephanie Planque; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  Front Immunol       Date:  2012-12-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.